Summary of CRISPR Therapeutics AG Conference Call Company Overview - **Company**: CRISPR Therapeutics AG (NASDAQ: CRSP) - **Date**: June 11, 2024 - **Participants**: Sam Kulkarni (CEO), Salveen Richter (Goldman Sachs) Key Points Industry and Company Focus - CRISPR Therapeutics is focusing on multiple verticals: cancer, ex-vivo non-cancer, regenerative medicine, and in vivo gene editing [2][3][5] - The company aims to balance its portfolio between rare and common diseases, believing CRISPR technology can impact both equally [2][3] Pipeline and R&D Strategy - The company has an approved drug, Casgevy, for sickle cell disease and thalassemia, marking a significant milestone [3] - CRISPR is leveraging its expertise in cell handling and technologies to develop best-in-class CAR-T therapies for cancer [3] - Regenerative medicine is viewed as an under-invested area with potential for significant impact on longevity and organ replacement [4] - In vivo gene editing is a growing focus, with plans for multiple programs targeting various organs [5] Innovation and Adaptation - CRISPR Therapeutics is committed to staying at the forefront of gene editing technology, adapting to innovations in the field [7][8] - The company has established a group called CRISPR X to explore next-generation applications of CRISPR technology [8] Delivery Technology - The company is shifting focus from viral delivery vehicles to lipid nanoparticles (LMPs) due to their safety and degradability [11][12] - LMPs are being explored for various organ systems, with ongoing challenges in non-liver applications [13] Commercial Portfolio and Casgevy Launch - The launch of Casgevy is seen as a significant opportunity, with high demand and supportive reimbursement from healthcare systems [15][16][17] - The company anticipates a long-term growth trajectory for Casgevy, differing from typical pharmaceutical launches [18] Reimbursement Landscape - The U.S. market has normalized its approach to rare disease pricing, with a better understanding of cell and gene therapies [20] - European markets are still adapting, with varying processes across countries [21] Patient Preferences - Patients show a preference for CRISPR-based therapies over traditional gene therapies when both options are available [24][25] Future Developments - The company is working on improving the preconditioning regimen for Casgevy to expand the patient population [26][27] - In vivo editing for hematopoietic cells is a long-term goal, with ongoing research into targeted LMPs [29] Cardiovascular Disease Trials - Upcoming data on cardiovascular disease trials is expected to provide insights into gene editing's effectiveness in reducing risk factors [31][32] Autoimmune Vertical - CRISPR is exploring opportunities in autoimmune diseases, particularly lupus, with a focus on CD19-directed cell therapies [34][36] - The company is well-positioned to compete in this space due to its unique approach and manufacturing capabilities [38] Oncology Portfolio - The oncology vertical remains a priority, with upcoming data expected to inform future strategies [41][44] - The company is advancing multiple CAR-T programs, including CTX-110 and CTX-112, targeting CD19 and CD70 [46] Regenerative Medicine - Regenerative medicine efforts are significant, particularly in developing stealth cells for Type 1 diabetes and other organ systems [48][50] Conclusion CRISPR Therapeutics AG is strategically positioned in the gene editing landscape, focusing on a diverse pipeline that includes cancer therapies, regenerative medicine, and autoimmune diseases. The company is adapting to technological advancements and market dynamics while maintaining a strong emphasis on patient needs and innovative delivery methods.

Core Viewpoint - CRISPR Therapeutics AG has gained attention in the market, with its stock performance showing a significant return compared to the broader market and its industry [1][2]. Stock Performance - Over the past month, CRISPR Therapeutics shares have returned +7.8%, outperforming the Zacks S&P 500 composite's +2.9% and the Zacks Medical - Biomedical and Genetics industry’s +1.2% [2]. Earnings Estimates - For the current quarter, CRISPR Therapeutics is expected to report a loss of $1.37 per share, reflecting a -39.8% change year-over-year, with a +9% revision in the consensus estimate over the last 30 days [5]. - The consensus earnings estimate for the current fiscal year is -$5.51, indicating a -184% change from the previous year, with a +2.2% revision in the last month [5]. - For the next fiscal year, the consensus estimate is -$4.44, showing a +19.5% change from the prior year, although this estimate has decreased by -1.3% recently [6]. Revenue Estimates - The consensus sales estimate for the current quarter is $8.39 million, indicating an -88% year-over-year change [9]. - For the current fiscal year, the sales estimate is $89.43 million, reflecting a -75.9% change, while the next fiscal year’s estimate of $531.75 million indicates a +494.6% change [9]. Recent Results - In the last reported quarter, CRISPR Therapeutics generated revenues of $0.5 million, a -99.5% year-over-year decline, and reported an EPS of -$1.43 compared to -$0.67 a year ago [10]. - The company had a revenue surprise of -93.94% against the Zacks Consensus Estimate of $8.31 million, but an EPS surprise of +12.27% [10]. - CRISPR Therapeutics has beaten consensus EPS estimates in each of the last four quarters and topped revenue estimates twice during this period [11]. Valuation - CRISPR Therapeutics is graded F in the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [15]. - Valuation multiples such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for assessing whether the stock is overvalued, fairly valued, or undervalued [13][14]. Market Outlook - The Zacks Rank for CRISPR Therapeutics is 3 (Hold), suggesting that the stock may perform in line with the broader market in the near term [7][16].

Core Viewpoint - CRISPR Therapeutics AG has experienced a 12% increase in share price over the past month, outperforming the S&P 500, raising questions about the sustainability of this trend leading up to the next earnings release [1]. Financial Performance - In Q1 2024, CRISPR Therapeutics reported a loss of $1.43 per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.63, compared to a loss of $0.67 per share in the same period last year [2]. - The company's total revenues were $0.5 million, significantly missing the Zacks Consensus Estimate of $8.3 million, and down from $100 million in the prior year, which was entirely from an upfront payment from Vertex [3]. Expense Analysis - Research and development expenses decreased by 24% year-over-year to $76.2 million, attributed to reduced external research and manufacturing costs [4]. - General and administrative expenses fell by 20% to $18.0 million, driven by lower employee-related and stock-based compensation expenses [4]. - Collaboration expenses rose by 11% year-over-year to $47.0 million, primarily due to increased commercial and manufacturing costs [4]. Cash Position - As of March 31, 2024, the company had cash, cash equivalents, marketable securities, and accounts receivables totaling $2.1 billion, up from $1.7 billion as of December 31, 2023, mainly due to proceeds from a direct offering and a $200 million milestone payment from Vertex [5]. Market Sentiment - Recent estimates for CRISPR Therapeutics have trended upward, with a consensus estimate shift of 18.14% [6]. - The company holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [8]. Industry Comparison - CRISPR Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where Biogen Inc. has seen a 4.2% gain over the past month, reporting revenues of $2.29 billion, a year-over-year decline of 7% [9]. - Biogen's expected earnings for the current quarter are $3.98 per share, reflecting a 1% decrease from the previous year, with a Zacks Rank 3 (Hold) and a VGM Score of B [10].

CRISPR Therapeutics AG (NASDAQ:CRSP) Jefferies 2024 Global Healthcare Conference June 5, 2024 10:00 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Maury Raycroft - Jefferies Maury Raycroft Good morning. My name is Maury Raycroft and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome the CEO of CRISPR Therapeutics Sam Kulkarni. Thanks so much for joining us today, Sam. We're going to do fireside chat format. So m ...

In keeping with Cathie Wood's style, these picks are riskier than average. Via her ARK Innovation ETF (ARKK 1.25%), portfolio manager Cathie Wood makes a lot of biotech bets, often on companies that are at the cutting edge of innovation in science and technology. Businesses like that tend to have volatile and temperamental stocks, though investors are lured back time and time again because they offer the possibility of big returns in exchange for significant risks. Does it make sense to invest in these stoc ...

Core Viewpoint - CRISPR Therapeutics AG has been a highly searched stock recently, indicating potential investor interest and market activity [1] Earnings Estimates - For the current quarter, CRISPR Therapeutics is expected to report a loss of $1.39 per share, reflecting a year-over-year change of -41.8% [5] - The Zacks Consensus Estimate for the current fiscal year is -$5.64, indicating a significant year-over-year change of -190.7% [5] - For the next fiscal year, the consensus estimate is -$4.50, showing a change of +20.1% from the previous year [6] - The consensus earnings estimate has changed +16.9% over the last 30 days for the current quarter and +9.6% for the current fiscal year [5][6] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $8.21 million, indicating a year-over-year decline of -88.3% [10] - For the current fiscal year, the sales estimate is $89.12 million, reflecting a -76% change, while the next fiscal year estimate is $550.06 million, indicating a growth of +517.2% [10] Last Reported Results and Surprise History - In the last reported quarter, CRISPR Therapeutics generated revenues of $0.5 million, a year-over-year decline of -99.5% [11] - The EPS for the same period was -$1.43, compared to -$0.67 a year ago, with a revenue surprise of -93.94% against the Zacks Consensus Estimate [11] - The company has beaten consensus EPS estimates in the last four quarters and topped revenue estimates twice during this period [12] Valuation - CRISPR Therapeutics has a Zacks Value Style Score of F, indicating it is trading at a premium compared to its peers [16] - Valuation multiples such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for assessing whether the stock is overvalued or undervalued [14][15] Overall Market Position - The Zacks Rank for CRISPR Therapeutics is 3 (Hold), suggesting it may perform in line with the broader market in the near term [7][17]

Core Viewpoint - CRISPR Therapeutics presents multiple investment opportunities through its commercialized product, a robust pipeline, and strong financial position [1][2] Group 1: Commercialized Product - Casgevy, CRISPR's first commercialized gene therapy for sickle cell disease and beta thalassemia, is in global rollout with approvals in the U.S., E.U., and U.K. [3] - Currently, there are 25 authorized treatment centers worldwide, with more expected to open, leading to increased patient eligibility and sales [4] - Improvements in the manufacturing process could expand the addressable market by making treatment less burdensome for patients [6] Group 2: Pipeline Programs - The R&D pipeline includes clinical-stage programs targeting large markets, such as the CTX 320 program for atherosclerotic cardiovascular disease, projected to reach $195.8 billion by 2030 [7] - Another program, CTX 310, aims to treat various dyslipidemias, with potential applications for general cholesterol reduction [8] - The diverse pipeline increases the likelihood of successful drug development, providing a bullish outlook for the future [9] Group 3: Financial Position - CRISPR Therapeutics has a strong balance sheet with approximately $2.1 billion in cash and equivalents, zero long-term debt, and minimal capital lease obligations [10] - With trailing-12-month operating expenses of $433.6 million, the company has ample financial resources and can secure additional funding if necessary [11] - The lack of financial pressure allows the company to invest strategically in growth opportunities [12]

-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Naimish Patel, M.D., as Chief Medical Officer, effective May 28, 2024. Dr. Patel is an experienced drug developer who has worked across a wide range of d ...

Core Viewpoint - CRISPR Therapeutics is positioned for significant growth with the recent approval of its gene therapy, Casgevy, which treats hereditary blood diseases, and is expected to generate substantial revenue in the coming quarters [1][4][5]. Financial Outlook - The company is projected to generate approximately $81 million in revenue for the current year, increasing to $356 million next year, primarily from Casgevy sales [5]. - Analysts do not expect profitability until after 2025, but some anticipate positive earnings per share (EPS) within the next 18 months, indicating potential progress towards profitability [6]. Pipeline and Growth Potential - CRISPR Therapeutics has a promising pipeline, including the CTX211 program for type 1 diabetes, which is in phase 1 trials and could tap into a nearly $39 billion market by 2029 if successful [8]. - Other advanced clinical programs target conditions such as renal cell carcinoma, B-cell malignancies, and atherosclerotic cardiovascular disease (ASCVD), which could further drive growth [9]. Market Position and Investment Considerations - The company's current market capitalization is around $4.8 billion, making it challenging to expect a tenfold increase in value in the near term [10]. - While the stock may not be a "millionaire-maker," it could still provide consistent value to long-term retail investors who are not seeking lottery-style returns [11][12].

Group 1: Market Overview - The stock market is experiencing significant growth, with the Nasdaq and S&P 500 reaching new record highs, indicating a bull market phase that is expected to last longer than bear markets [1][2] - Historical data shows that the average bull market lasts nearly nine years, while bear markets last approximately 1.4 years, suggesting ample time for investors to benefit from current market conditions [2] Group 2: Biotech Industry Potential - The biotech industry presents numerous investment opportunities, particularly for companies that have recently received product approvals, signaling strong growth potential [3] - Companies with solid long-term prospects are likely to provide returns that extend beyond the current bull market [2] Group 3: CRISPR Therapeutics - CRISPR Therapeutics has received regulatory approval for Casgevy, a treatment for sickle cell disease and beta thalassemia, marking the first approval of a CRISPR-based treatment [4][5] - The company has over 25 authorized treatment centers ready to launch Casgevy, with multiple patients already in the treatment process, indicating strong initial demand [5] - CRISPR is also developing a lighter conditioning treatment and in vivo gene editing of stem cells, which could broaden the application of its technology and enhance patient uptake [6] - The stock is currently trading lower than in previous years, presenting a buying opportunity for growth investors as the Casgevy launch progresses [7] Group 4: Iovance Biotherapeutics - Iovance Biotherapeutics specializes in tumor infiltrating lymphocyte (TIL) treatments and has received approval for Amtagvi, its first commercialized TIL product for advanced melanoma [8][9] - The company reports that over 100 patients have enrolled for Amtagvi since its approval, with plans to establish 50 authorized treatment centers by the end of the month and over 70 by year-end [10] - Amtagvi has received reimbursement approvals from payers covering over 200 million people, enhancing accessibility for patients in need [11] - Iovance is also leveraging its technology across its pipeline, indicating potential for additional growth drivers in the future [12]